Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial

Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial

Background: Nonalcoholic steatohepatitis (NASH) is associated with increased cardiovascular risk and mortality. No US Food and Drug Administration (FDA) approved therapies for NASH are available; clinical trials to date have not yet systematically assessed for changes in cardiovascular risk. This st...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Steven C. Lin, Brandon Ang, Carolyn Hernandez, Ricki Bettencourt, Rashmi Jain, Joanie Salotti, Lisa Richards, Yuko Kono, Archana Bhatt, Hamed Aryafar, Grace Y. Lin, Mark A. Valasek, Claude B. Sirlin, Sharon Brouha, Rohit Loomba
פורמט: Article
שפה:English
יצא לאור: SAGE Publishing 2016-03-01
סדרה:Therapeutic Advances in Gastroenterology
גישה מקוונת:https://doi.org/10.1177/1756283X15621232

פריטים דומים

פריטים דומים